SCHEDULE 13G/A: RA Capital Management Reduces Stake in BioAge Labs, Now Holds Below 5%

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of BioAge Labs, Inc. common stock to below 5% as of December 31, 2024.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") filed an amendment to their Schedule 13G for BioAge Labs, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially owned 1,310,589 shares of BioAge Labs, Inc. Common Stock.
• This aggregate ownership represents 3.7% of the Issuer's outstanding Common Stock, based on 35,848,738 shares outstanding as of October 31, 2024.
• RA Capital Healthcare Fund, L.P. directly holds 982,942 shares (2.7% of class), while RA Capital Nexus Fund III, L.P. directly holds 327,647 shares.
• The filing indicates that the Reporting Persons now own 5 percent or less of the class, implying a reduction from a previous holding that was above 5%.
• The Reporting Persons disclaim status as a 'group' for purposes of this Schedule 13G and certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the disclosed reduction in a significant institutional investor's stake to below 5%, which can be interpreted as a decrease in conviction, despite the filing being a routine disclosure.

Positives

• Continued investment by RA Capital Management, a prominent healthcare-focused investment firm, indicates ongoing interest in BioAge Labs, Inc.

Negatives

• The reduction in beneficial ownership by RA Capital Management and its affiliates to below 5% could be perceived negatively by the market, potentially signaling a decreased conviction or a reallocation of capital by a significant institutional investor.

Risks

• The Reporting Persons' investment is passive, meaning they do not intend to influence or change the control of BioAge Labs, Inc., which limits their direct impact on the company's strategic direction.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding BioAge Labs, Inc.'s future operations or financial performance.

Industry Context

RA Capital Management is a prominent investment firm specializing in the healthcare and life sciences sectors, often investing in biotechnology companies like BioAge Labs, Inc. This filing reflects a routine disclosure of changes in their passive investment stake within the industry.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional investor's stake may influence investor sentiment and potentially the stock price.

Key Dates

Keywords

BioAge Labs, RA Capital Management, Schedule 13G/A, beneficial ownership, investment, biotechnology, healthcare, institutional investor, passive investment